Gapping up
In reaction to earnings/guidance:
In reaction to earnings/guidance:
- ALK +1.2% (guidance), NDSN +1.1%
Other news:
- CDXS +13.9% (enters into agreement with Aldevron)
- CARM +12.7% (announces nomination of first lead candidate under its collaboration with Moderna (MRNA))
- ESPR +11.9% (FDA updates LDL-C for NEXLETOL and NEXLIZET)
- MRNA +11.7% (Moderna and Merck (MRK) announce mRNA-4157 in combination with Keytruda demonstrated continued improvement in recurrence-free survival and distant metastasis-free survival in patients with high-risk stage III/IV melanoma following complete resection versus Keytruda at three years)
- GKOS +6.8% (FDA approved its New Drug Application for a single administration per eye of iDose TR 75 mcg; reaffirms FY23 revenue guidance and sees FY24 revs above consensus)
- SDRL +5.2% (initiates new share buy-back program)
- HOOD +3.3% (reports November data)
- BCYC +3.2% (provides data updates for three clinical programs and strategy overview at First R&D Day)
- ISPR +3% (subsidiary enters five-year exclusive global manufacturing and distribution agreement with lifestyle brand: BrkFst)
- RKLB +2.4% (preparing launch of its Electron missino)
- TXG +2.4% (releases data from new study)
- CVE +2.4% (announces 2024 budget)
- TEX +2.4% (Director disclosed the purchase of 50000 shares at $50.69 - $51.20 worth nearly $2.6 mln)
- NX +2.3% (CEO to become Chairman)
- OXY +2.2% (Warren Buffett's Berkshire Hathaway bought another 10482162 shares worth approx. $589 mln (12/11-12/13 transaction dates))
- CHSN +2.1% (expanding its new coffee brand in China)
- RILY +1.9% (continued volatility)
- TOL +1.8% (authorizes new repurchase plan)
- MAT +1.7% (developing American Girl doll film)
- SDGR +1.5% (Highlights Progress of Clinical Programs and Discloses Three New Programs at First Therapeutics Pipeline Investor Event)
- JMIA +1.2% (closing food delivery business)
- DWAC +1.1% (received termination notices from PIPE Investors representing approximately $17500000 of the PIPE between November 2 2023 and November 20 2023)
- AEO +1% (raises dividend)
- EOG +1% (names new COO and CFO)
Analyst comments:
- ALEC +10% (upgraded to Buy from Hold at Stifel)
- IBP +2.7% (upgraded to Overweight from Neutral at JP Morgan)
- IVZ +2.6% (upgraded to Outperform from Mkt Perform at Keefe Bruyette)
- BLD +2.5% (upgraded to Overweight from Neutral at JP Morgan)
- LYV +2.3% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- HST +2.2% (upgraded to Neutral from Underweight at JP Morgan)
- BECN +2% (upgraded to Overweight from Neutral at JP Morgan)
- CHH +1.2% (upgraded to Neutral from Underweight at JP Morgan)